Hamburg, Germany -05 October 2011: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.
As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against a selected number of targets. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.
Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals of the research collaboration with early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.
Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: "We are extremely pleased that UCB has again selected Evotec to collaborate on this second significant Drug Discovery Collaboration. This integrated drug discovery deal showcases our broad target class expertise coupled with our industry leading platform. We look forward to a fruitful collaboration with our scientific colleagues and friends at UCB."
Dr Ismail Kola, President, UCB NewMedicines commented: "Evotec is the ideal partner to provide the resource bandwidth and drug-hunting expertise to complement our internal efforts to progress this strategically important program."
No financial details are disclosed.